1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Musculoskeletal conditions
  5. Arthritis

Golimumab for the treatment of psoriatic arthritis

Technology appraisal guidance [TA220] Published date: 27 April 2011

  • Guidance
  • Tools and resources
  • Information for the public
  • Evidence
  • History
  • Overview
  • 1 Guidance
  • 2 The technology
  • 3 The manufacturer's submission
  • 4 Consideration of the evidence
  • 5 Implementation
  • 6 Recommendation for further research
  • 7 Related NICE guidance
  • 8 Review of guidance
  • Appendix A: Appraisal Committee members and NICE project team
  • Appendix B: Sources of evidence considered by the Committee
  • Changes after publication
  • About this guidance
Download guidance

Guidance

  • Next

Changes after publication

Changes after publication

February 2014: implementation section updated to clarify that golimumab is recommended as an option for treating psoriatic arthritis. Additional minor maintenance update also carried out.

March 2012: minor maintenance

  • National Institute for Health and Care Excellence (NICE)

  • Next